FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2802589270> ?p ?o ?g. }

• W2802589270 endingPage "1217" @default.
• W2802589270 startingPage "1209" @default.
• W2802589270 abstract "We performed an observational study on the efficacy of ben-damustine and rituximab (BR) as first salvage regimen in chronic lymphocytic leukemia (CLL). In an intention-to-treat analysis including 237 patients, the median progression-free survival (PFS) was 25 months. The presence of del(17p), unmutated IGHV and advanced stage were associated with a shorter PFS at multivariate analysis. The median time-to-next treatment was 31.3 months. Front-line treatment with a chemoimmunotherapy regimen was the only predictive factor for a shorter time to next treatment at multivariate analysis. The median overall survival (OS) was 74.5 months. Advanced disease stage (i.e. Rai stage III-IV or Binet stage C) and resistant disease were the only parameters significantly associated with a shorter OS. Grade 3-5 infections were recorded in 6.3% of patients. A matched-adjusted indirect comparison with ibrutinib given second-line within Named Patient Programs in the United Kingdom and in Italy was carried out with OS as objective end point. When restricting the analysis to patients with intact 17p who had received chemoimmunotherapy in first line, there was no difference in OS between patients treated with ibrutinib (63% alive at 36 months) and patients treated with BR (74.4% alive at 36 months). BR is an efficacious first salvage regimen in CLL in a real-life population, including the elderly and unfit patients. BR and ibrutinib may be equally effective in terms of OS when used as first salvage treatment in patients without 17p deletion." @default.
• W2802589270 created "2018-05-17" @default.
• W2802589270 creator A5005056682 @default.
• W2802589270 creator A5008054206 @default.
• W2802589270 creator A5008546299 @default.
• W2802589270 creator A5009431453 @default.
• W2802589270 creator A5011435773 @default.
• W2802589270 creator A5012590429 @default.
• W2802589270 creator A5013236194 @default.
• W2802589270 creator A5013919257 @default.
• W2802589270 creator A5020702876 @default.
• W2802589270 creator A5021492292 @default.
• W2802589270 creator A5027193172 @default.
• W2802589270 creator A5030806032 @default.
• W2802589270 creator A5035820057 @default.
• W2802589270 creator A5036055911 @default.
• W2802589270 creator A5038163660 @default.
• W2802589270 creator A5039504007 @default.
• W2802589270 creator A5039819830 @default.
• W2802589270 creator A5041326568 @default.
• W2802589270 creator A5041745367 @default.
• W2802589270 creator A5041966654 @default.
• W2802589270 creator A5042513487 @default.
• W2802589270 creator A5045240242 @default.
• W2802589270 creator A5046680192 @default.
• W2802589270 creator A5053298824 @default.
• W2802589270 creator A5056554686 @default.
• W2802589270 creator A5056886751 @default.
• W2802589270 creator A5061896020 @default.
• W2802589270 creator A5062047451 @default.
• W2802589270 creator A5062538385 @default.
• W2802589270 creator A5065081503 @default.
• W2802589270 creator A5068687462 @default.
• W2802589270 creator A5070924011 @default.
• W2802589270 creator A5074839524 @default.
• W2802589270 creator A5078192708 @default.
• W2802589270 creator A5078295579 @default.
• W2802589270 creator A5079400134 @default.
• W2802589270 creator A5080861890 @default.
• W2802589270 creator A5089025495 @default.
• W2802589270 creator A5090615083 @default.
• W2802589270 creator A5090624182 @default.
• W2802589270 creator A5091887568 @default.
• W2802589270 date "2018-04-19" @default.
• W2802589270 modified "2023-10-16" @default.
• W2802589270 title "Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study" @default.
• W2802589270 cites W1493658394 @default.
• W2802589270 cites W1554993461 @default.
• W2802589270 cites W2040501000 @default.
• W2802589270 cites W2066357502 @default.
• W2802589270 cites W2066564017 @default.
• W2802589270 cites W2071549499 @default.
• W2802589270 cites W2073938584 @default.
• W2802589270 cites W2103857518 @default.
• W2802589270 cites W2108206643 @default.
• W2802589270 cites W2142099365 @default.
• W2802589270 cites W2149515595 @default.
• W2802589270 cites W2191219754 @default.
• W2802589270 cites W2192121806 @default.
• W2802589270 cites W2337485820 @default.
• W2802589270 cites W2396328865 @default.
• W2802589270 cites W2399623634 @default.
• W2802589270 cites W2557801192 @default.
• W2802589270 cites W2558394416 @default.
• W2802589270 cites W2570921003 @default.
• W2802589270 cites W2581658669 @default.
• W2802589270 cites W2587810027 @default.
• W2802589270 cites W2595396118 @default.
• W2802589270 cites W2623762297 @default.
• W2802589270 cites W2741624292 @default.
• W2802589270 cites W2744781811 @default.
• W2802589270 cites W2795456460 @default.
• W2802589270 doi "https://doi.org/10.3324/haematol.2018.189837" @default.
• W2802589270 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6029555" @default.
• W2802589270 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29674504" @default.
• W2802589270 hasPublicationYear "2018" @default.
• W2802589270 type Work @default.
• W2802589270 sameAs 2802589270 @default.
• W2802589270 citedByCount "29" @default.
• W2802589270 countsByYear W28025892702018 @default.
• W2802589270 countsByYear W28025892702019 @default.
• W2802589270 countsByYear W28025892702020 @default.
• W2802589270 countsByYear W28025892702021 @default.
• W2802589270 countsByYear W28025892702022 @default.
• W2802589270 countsByYear W28025892702023 @default.
• W2802589270 crossrefType "journal-article" @default.
• W2802589270 hasAuthorship W2802589270A5005056682 @default.
• W2802589270 hasAuthorship W2802589270A5008054206 @default.
• W2802589270 hasAuthorship W2802589270A5008546299 @default.
• W2802589270 hasAuthorship W2802589270A5009431453 @default.
• W2802589270 hasAuthorship W2802589270A5011435773 @default.
• W2802589270 hasAuthorship W2802589270A5012590429 @default.
• W2802589270 hasAuthorship W2802589270A5013236194 @default.
• W2802589270 hasAuthorship W2802589270A5013919257 @default.
• W2802589270 hasAuthorship W2802589270A5020702876 @default.
• W2802589270 hasAuthorship W2802589270A5021492292 @default.
• W2802589270 hasAuthorship W2802589270A5027193172 @default.
• W2802589270 hasAuthorship W2802589270A5030806032 @default.

• next